renal transplant immunosuppression Flashcards
intial
ciclosporin/tacrolimus with a monoclonal antibody
maintainance
ciclosporin/tacrolimus with MMF or sirolimus
when do you add steriods in renal transplant
add steroids if more than one steroid responsive acute rejection episode
what does ciclosporin do
inhibits calcineurin, a phosphotase involved in T cell activation
what does tacrolimus do
lower incidence of acute rejection compared to ciclosporin
also less hypertension and hyperlipidaemia
however, high incidence of impaired glucose tolerance and diabetes
tacrolimus side effects
impaired glucose tolerance and diabetes
Mycophenolate mofetil does what
blocks purine synthesis by inhibition of IMPDH
therefore inhibits proliferation of B and T cells
side effect of MMF
GI and marrow suppression
sirolimus
blocks T cell proliferation by blocking the IL-2 receptor
complications of renal transplant
cardiovascular
renal failure
malignancy
Cardiovascular disease - tacrolimus and ciclosporin can cause hypertension and hyperglycaemia.
Tacrolimus can also cause hyperlipidaemia.
Renal failure - due to nephrotoxic effects of tacrolimus and ciclosporin/graft rejection/recurrence of original disease in transplanted kidney
Malignancy - minimising sun exposure to reduce the risk of squamous cell carcinomas and basal cell carcinomas
3 types of organ rejection
Types of organ rejection
Hyperacute. This occurs immediately through presence of pre formed antigens (such as ABO incompatibility).
Acute. Occurs during the first 6 months and is usually T cell mediated. Usually tissue infiltrates and vascular lesions.
Chronic. Occurs after the first 6 months. Vascular changes predominate.
Patients with end stage renal failure who are dialysis dependent or likely to become so in the immediate future are considered for transplant. Exclusion criteria for renal transplant
active malignancy, old age
A Rutherford-Morrison incision is made on the preferred side. This provides excellent extraperitoneal access to the iliac vessels. The external iliac artery and vein are dissected out and following systemic heparinisation are cross clamped. The vein and artery are anastamosed to the iliacs and the clamps removed. The ureter is then implanted into the bladder and a stent is usually placed to maintain patency. The wounds are then closed and the patient recovered from surgery.
In the immediate phase a common problem encountered in cadaveric kidneys is acute tubular necrosis and this tends to resolve.
Graft survival times from cadaveric donors are typically of the order of 9 years and monozygotic twin transplant (live donor) may survive as long as 25 years.